
Mark A Hlatky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9425087/publications.pdf Version: 2024-02-01



MADE A HIATEV

#	Article	IF	CITATIONS
1	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
2	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
3	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
4	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1082-e1143.	1.6	2,380
5	measurement and reporting of intravascular ultrasound studies (ivus)31When citing this document, the American College of Cardiology would appreciate the following citation format: Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. ACC Clinical Expert Consensus Document on Standards for the acquisition. measurement and	2.8	2,009
6	reporting of intravascul. Journal of the American College of Cardiology, 2001, 37, 1478-1492. Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186.	21.4	1,818
7	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology, 2008, 51, e1-e62.	2.8	1,798
8	A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New England Journal of Medicine, 2009, 360, 2503-2515.	27.0	1,705
9	Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy. JAMA - Journal of the American Medical Association, 2002, 288, 49.	7.4	1,586
10	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, e285-e350.	2.8	1,550
11	Comparison of Coronary Bypass Surgery with Angioplasty in Patients with Multivessel Disease. New England Journal of Medicine, 1996, 335, 217-225.	27.0	1,445
12	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 1687-1713.	2.8	1,444
13	A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status) Tj ETQq1 1 0.	.784314 rş 1.6	gBT /Overlock 1,422
14	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2008, 117, e350-408.	1.6	1,358
15	Increasing value and reducing waste in research design, conduct, and analysis. Lancet, The, 2014, 383, 166-175.	13.7	1,186
16	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology, 2010, 56, e50-e103.	2.8	1,150
17	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ACS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology, 2019, 73, 3168-3209.	2.8	1,128
18	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Circulation, 2010, 122, e584-636.	1.6	1,009

#	Article	IF	CITATIONS
19	Criteria for Evaluation of Novel Markers of Cardiovascular Risk. Circulation, 2009, 119, 2408-2416.	1.6	998
20	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	2.8	991
21	ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Summary Article. Circulation, 2002, 106, 2145-2161.	1.6	907
22	ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain. Journal of the American College of Cardiology, 2007, 49, 378-402.	2.8	891
23	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2013, 127, e283-352.	1.6	803
24	Prognostic Value of a Treadmill Exercise Score in Outpatients with Suspected Coronary Artery Disease. New England Journal of Medicine, 1991, 325, 849-853.	27.0	751
25	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology, 2013, 61, e6-e75.	2.8	736
26	ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices—Summary Article. Journal of the American College of Cardiology, 2002, 40, 1703-1719.	2.8	686
27	Depressive Symptoms and Health-Related Quality of Life. JAMA - Journal of the American Medical Association, 2003, 290, 215.	7.4	669
28	Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, The, 2009, 373, 1190-1197.	13.7	649
29	Conference. Journal of the American College of Cardiology, 1998, 31, 1175-1206.	2.8	579
30	Exercise Treadmill Score for Predicting Prognosis in Coronary Artery Disease. Annals of Internal Medicine, 1987, 106, 793.	3.9	554
31	ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring by Computed Tomography in Clobal Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain. Circulation, 2007, 115, 402-426.	1.6	552
32	Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction. New England Journal of Medicine, 1995, 332, 1418-1424.	27.0	522
33	Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet, The, 2018, 391, 939-948.	13.7	506
34	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2007, 297, 2502.	7.4	497
35	Cost-Effectiveness of Implantable Cardioverter–Defibrillators. New England Journal of Medicine, 2005, 353, 1471-1480.	27.0	492
36	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2018, 138, e272-e391.	1.6	468

#	Article	IF	CITATIONS
37	Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR _{CT} : outcome and resource impacts study. European Heart Journal, 2015, 36, 3359-3367.	2.2	467
38	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. Heart Rhythm, 2018, 15, e190-e252.	0.7	448
39	Contrast Nephrotoxicity: A Randomized Controlled Trial of a Nonionic and an Ionic Radiographic Contrast Agent. New England Journal of Medicine, 1989, 320, 149-153.	27.0	407
40	Chronic Kidney Disease and CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2019, 74, 1823-1838.	2.8	403
41	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology, 2008, 52, 1502-1517.	2.8	390
42	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Journal of the American College of Cardiology, 2018, 72, 1677-1749.	2.8	382
43	The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. Journal of the American College of Cardiology, 2001, 38, 478-485.	2.8	367
44	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Heart Rhythm, 2008, 5, 934-955.	0.7	367
45	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1046-e1081.	1.6	361
46	ACC/AHA Statement on Cost/Value Methodology in ClinicalÂPractice Guidelines and Performance Measures. Journal of the American College of Cardiology, 2014, 63, 2304-2322.	2.8	353
47	ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. Journal of the American College of Cardiology, 2012, 60, 2427-2463.	2.8	352
48	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary. Circulation, 2010, 122, 2748-2764.	1.6	333
49	ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures. Circulation, 2014, 129, 2329-2345.	1.6	329
50	A Comparison of Thrombolytic Therapy with Primary Coronary Angioplasty for Acute Myocardial Infarction. New England Journal of Medicine, 1996, 335, 1253-1260.	27.0	326
51	Use of Medical Resources and Quality of Life after Acute Myocardial Infarction in Canada and the United States. New England Journal of Medicine, 1994, 331, 1130-1135.	27.0	322
52	Factors affecting sensitivity and specificity of exercise electrocardiography. American Journal of Medicine, 1984, 77, 64-71.	1.5	318
53	1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease. Journal of the American College of Cardiology, 2016, 68, 435-445. American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert	2.8	313
54	Consensus Document on Cardiac Catheterization Laboratory Standards41When citing this document, the American College of Cardiology and the Society for Cardiac Angiography and Interventions would appreciate the following citation format: Bashore TM, Bates ER, Berger PB, Clark DA, Cusma JT, Dehmer GJ, Kern MJ, Laskey WK, O'Laughlin MP, Oesterle S, Popma JJ. Cardiac catheterization laboratory standards: a report of. Journal of the American College of Cardiology, 2001, 37, 2170-2214.	2.8	308

#	Article	IF	CITATIONS
55	Medical Care Costs and Quality of Life after Randomization to Coronary Angioplasty or Coronary Bypass Surgery. New England Journal of Medicine, 1997, 336, 92-99.	27.0	303
56	Meta-analysis of Trials Comparing β-Blockers, Calcium Antagonists, and Nitrates for Stable Angina. JAMA - Journal of the American Medical Association, 1999, 281, 1927.	7.4	303
57	ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary. Circulation, 1998, 97, 1325-1335.	1.6	296
58	ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting. Journal of the American College of Cardiology, 2007, 49, 126-170.	2.8	295
59	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Heart Rhythm, 2008, 5, e1-e62.	0.7	283
60	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation, 2010, 122, 2619-2633.	1.6	281
61	Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery. Annals of Internal Medicine, 2007, 147, 703.	3.9	265
62	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.7	262
63	Cardiac rupture, mortality and the timing of thrombolytic therapy: A meta-analysis. Journal of the American College of Cardiology, 1990, 16, 359-367.	2.8	261
64	Procedural Complications, Rehospitalizations, and Repeat Procedures After Catheter Ablation for Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 59, 143-149.	2.8	259
65	Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy. JAMA - Journal of the American Medical Association, 2002, 287, 591.	7.4	252
66	Rheumatoid arthritis and cardiovascular disease. American Heart Journal, 2013, 166, 622-628.e1.	2.7	251
67	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation, 2018, 138, e210-e271.	1.6	250
68	ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure. Journal of the American College of Cardiology, 2005, 46, 1144-1178.	2.8	249
69	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1243-1275.	0.8	249
70	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. Circulation, 2010, 121, 2509-2543.	1.6	247
71	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. Journal of the American College of Cardiology, 2010, 55, 2663-2699.	2.8	244
72	Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. American Journal of Cardiology, 1986, 58, 1181-1187.	1.6	229

#	Article	IF	CITATIONS
73	Cardiovascular and Renal Toxicity of a Nonionic Radiographic Contrast Agent after Cardiac Catheterization. Annals of Internal Medicine, 1989, 110, 119.	3.9	225
74	ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure. Circulation, 2005, 112, 1853-1887.	1.6	221
75	Cost-Effectiveness of Preparticipation Screening for Prevention of Sudden Cardiac Death in Young Athletes. Annals of Internal Medicine, 2010, 152, 276.	3.9	211
76	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology, 2010, 56, 2051-2066.	2.8	203
77	Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve–Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Circulation, 2018, 137, 480-487.	1.6	193
78	Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables Circulation, 1990, 82, 1705-1717.	1.6	188
79	Patient Management After Noninvasive Cardiac Imaging. Journal of the American College of Cardiology, 2012, 59, 462-474.	2.8	188
80	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Journal of the American College of Cardiology, 2008, 51, 2085-2105.	2.8	184
81	Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association. Circulation, 2017, 136, e172-e194.	1.6	184
82	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Circulation, 2008, 117, 2820-2840.	1.6	175
83	Association of Coronary CT Angiography or Stress Testing With Subsequent Utilization and Spending Among Medicare Beneficiaries. JAMA - Journal of the American Medical Association, 2011, 306, 2128-36.	7.4	171
84	Digoxin Immune Fab therapy in the management of digitalis intoxication: Safety and efficacy results of an observational surveillance study. Journal of the American College of Cardiology, 1991, 17, 590-598.	2.8	169
85	Validation of a New Brief Physical Activity Survey among Men and Women Aged 60–69 Years. American Journal of Epidemiology, 2006, 164, 598-606.	3.4	169
86	Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery. New England Journal of Medicine, 2022, 386, 128-137.	27.0	169
87	Variation among Hospitals in Coronary-Angiography Practices and Outcomes after Myocardial Infarction in a Large Health Maintenance Organization. New England Journal of Medicine, 1996, 335, 1888-1896.	27.0	168
88	Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Human Molecular Genetics, 2008, 17, 2320-2328.	2.9	166
89	Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System. Circulation, 2016, 133, 1426-1428.	1.6	166
90	Cost-Effectiveness of Implantable Cardioverter Defibrillators Relative to Amiodarone for Prevention of Sudden Cardiac Death. Annals of Internal Medicine, 1997, 126, 1.	3.9	164

#	Article	IF	CITATIONS
91	Quality-of-Life and Economic Outcomes ofÂAssessing Fractional Flow Reserve With Computed Tomography Angiography. Journal of the American College of Cardiology, 2015, 66, 2315-2323.	2.8	164
92	2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vascular Medicine, 2017, 22, NP1-NP43.	1.5	162
93	Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. American Journal of Cardiology, 1987, 60, 766-770.	1.6	157
94	Preventing heart attack and death in patients with coronary disease. Journal of the American College of Cardiology, 1995, 26, 292.	2.8	157
95	Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System. Journal of the American College of Cardiology, 2016, 67, 1572-1574.	2.8	154
96	Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. Journal of the American College of Cardiology, 1988, 11, 237-245.	2.8	153
97	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. American Journal of Gastroenterology. 2010. 105. 2533-2549.	0.4	153
98	Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. Journal of the American College of Cardiology, 1988, 11, 20-26.	2.8	152
99	Characterizing the admixed African ancestry of African Americans. Genome Biology, 2009, 10, R141.	9.6	145
100	Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. American Journal of Cardiology, 1991, 68, 973-975.	1.6	141
101	Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension. Chest, 2004, 126, 1452-1459.	0.8	139
102	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. American Journal of Gastroenterology, 2008, 103, 2890-2907.	0.4	137
103	Screening for Sudden Cardiac Death in the Young. Circulation, 2011, 123, 1911-1918.	1.6	137
104	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary. Journal of the American College of Cardiology, 2010, 56, 2182-2199.	2.8	133
105	Evaluating Quality of Care for Patients With Heart Failure. Circulation, 2000, 101, E122-40.	1.6	130
106	Differences in Medical Care and Disease Outcomes Among Black and White Women With Heart Disease. Circulation, 2003, 108, 1089-1094.	1.6	129
107	Metabolic Syndrome and Early-Onset Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 48, 1800-1807.	2.8	128
108	Multivessel Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in ESRD. Journal of the American Society of Nephrology: JASN, 2012, 23, 2042-2049.	6.1	128

#	Article	IF	CITATIONS
109	Integrating Complementary Medicine Into Cardiovascular Medicine. Journal of the American College of Cardiology, 2005, 46, 184-221.	2.8	126
110	Job Strain and the Prevalence and Outcome of Coronary Artery Disease. Circulation, 1995, 92, 327-333.	1.6	124
111	Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. American Journal of Cardiology, 1989, 63, 409-413.	1.6	123
112	Beta-Blocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease. Journal of the American College of Cardiology, 2014, 64, 247-252.	2.8	113
113	Quantitative Overview of Randomized Trials of Amiodarone to Prevent Sudden Cardiac Death. Circulation, 1997, 96, 2823-2829.	1.6	112
114	Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). American Journal of Medicine, 2001, 110, 260-266.	1.5	111
115	Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves. Circulation, 2016, 133, 680-686.	1.6	111
116	Task force 6. Cost effectiveness of assessment and management of risk factors. Journal of the American College of Cardiology, 1996, 27, 1020-1030.	2.8	107
117	Synthesizing Lessons Learned From Get With The Guidelines. Circulation, 2013, 128, 2447-2460.	1.6	106
118	Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. American Journal of Cardiology, 1990, 65, 28-34.	1.6	105
119	Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: Analysis of 8,517 patients. American Journal of Cardiology, 1990, 65, 1481-1484.	1.6	105
120	Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. Journal of the American College of Cardiology, 1988, 11, 1141-1149.	2.8	104
121	Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part I. Circulation, 2002, 106, 516-520.	1.6	104
122	Utilization and Outcomes of Measuring Fractional Flow Reserve in Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2020, 75, 409-419.	2.8	104
123	Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. Journal of Clinical Epidemiology, 1993, 46, 261-271.	5.0	103
124	Association of Spontaneous Bleeding and Myocardial Infarction With Long-Term Mortality After Percutaneous CoronaryÂIntervention. Journal of the American College of Cardiology, 2015, 65, 1411-1420.	2.8	101
125	2020 ACC/AHA guideline for the management of patients with valvular heart disease. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e183-e353.	0.8	100
126	Attitudes of women toward hormone therapy and prevention of heart disease. American Heart Journal, 1995, 129, 1237-1238.	2.7	99

#	Article	IF	CITATIONS
127	Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. JACC: Heart Failure, 2017, 5, 110-119.	4.1	97
128	Functional Testing or Coronary Computed Tomography Angiography in Patients With StableÂCoronary Artery Disease. Journal of the American College of Cardiology, 2017, 69, 1761-1770.	2.8	97
129	Association of β-Blocker Therapy With Risks of Adverse Cardiovascular Events and Deaths in Patients With Ischemic Heart Disease Undergoing Noncardiac Surgery. JAMA Internal Medicine, 2014, 174, 336.	5.1	96
130	PCSK9 Inhibitors. Journal of the American College of Cardiology, 2017, 70, 2677-2687.	2.8	96
131	Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation. Circulation, 2012, 125, 57-64.	1.6	94
132	Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. American Journal of Cardiology, 1991, 67, 225-230.	1.6	93
133	Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease. Circulation, 2004, 110, 1960-1966.	1.6	93
134	Isolated Disease of the Proximal Left Anterior Descending Artery. JACC: Cardiovascular Interventions, 2008, 1, 483-491.	2.9	92
135	Prognostic significance of precordial ST-segment depression during inferior acute myocardial infarction. American Journal of Cardiology, 1985, 55, 325-329.	1.6	89
136	Estimating the likelihood of severe coronary artery disease. American Journal of Medicine, 1991, 90, 553-562.	1.5	89
137	Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2018, 72, 386-398.	2.8	89
138	Trends in the Incidence of Atrial Fibrillation in Older Patients Initiating Dialysis in the United States. Circulation, 2012, 126, 2293-2301.	1.6	88
139	Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. Journal of the American College of Cardiology, 2003, 41, 1732-1738.	2.8	87
140	Cost-Effectiveness of Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease and Abnormal Fractional Flow Reserve. Circulation, 2013, 128, 1335-1340.	1.6	86
141	Clinical Data Bases. Medical Care, 1985, 23, 623-647.	2.4	85
142	A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multivessel coronary artery disease. American Journal of Cardiology, 1995, 76, 1025-1029.	1.6	85
143	STâ€elevation myocardial Infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of STâ€elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.	1.7	85
144	Catheterization and Cardiovascular Interventions, 2016, 87, 1001-1019. Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies. Journal of the American College of Cardiology, 2010, 56, 1552-1563.	2.8	84

#	Article	IF	CITATIONS
145	Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome. Annals of Internal Medicine, 2014, 160, 221-232.	3.9	84
146	Estimating the likelihood of severe coronary artery disease. American Journal of Medicine, 1991, 90, 553-562.	1.5	83
147	Obesity, Physical Activity, and Their Interaction in Incident Atrial Fibrillation in Postmenopausal Women. Journal of the American Heart Association, 2014, 3, .	3.7	83
148	Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. American Heart Journal, 2005, 149, 434-443.	2.7	82
149	Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. American Heart Journal, 2007, 154, 1035-1042.	2.7	82
150	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 836-849.	5.2	80
151	Statin and β-Blocker Therapy and the Initial Presentation of Coronary Heart Disease. Annals of Internal Medicine, 2006, 144, 229.	3.9	78
152	Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. American Heart Journal, 2002, 144, 440-448.	2.7	77
153	Risk factors for atrial fibrillation and their population burden in postmenopausal women: the Women's Health Initiative Observational Study. Heart, 2013, 99, 1173-1178.	2.9	76
154	Use of Medicare Data to Identify Coronary Heart Disease Outcomes in the Women's Health Initiative. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 157-162.	2.2	76
155	The Relation Between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation From the Implantable Cardioverter-Defibrillator Registry. Journal of the American College of Cardiology, 2010, 56, 1133-1139.	2.8	74
156	Traditional and new composite endpoints inÂheart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489.	7.1	74
157	Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial. European Heart Journal, 2021, 42, 3844-3852.	2.2	74
158	Painless exercise ST deviation on the treadmill: Long-term prognosis. Journal of the American College of Cardiology, 1989, 14, 885-892.	2.8	72
159	Diagnostic accuracy of cardiologists compared with probability calculations using Bayes' rule. American Journal of Cardiology, 1982, 49, 1927-1931.	1.6	71
160	Projected Costs and Consequences of Computed Tomographyâ€Determined Fractional Flow Reserve. Clinical Cardiology, 2013, 36, 743-748.	1.8	71
161	Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction. Annals of Internal Medicine, 2001, 135, 870.	3.9	70
162	Cost-Effectiveness of Coronary Artery Bypass Grafts Versus Percutaneous Coronary Intervention for Revascularization of High-Risk Patients. Circulation, 2006, 114, 1251-1257.	1.6	70

#	Article	IF	CITATIONS
163	Risk of Cardiovascular Events Associated With Current Exposure to HIV Antiretroviral Therapies in a US Veteran Population. Clinical Infectious Diseases, 2015, 61, 445-452.	5.8	70
164	Tying clinical research to patient care by use of an observational database. Statistics in Medicine, 1984, 3, 375-384.	1.6	69
165	Rheumatoid Arthritis, Anti–Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative. Arthritis and Rheumatology, 2015, 67, 2311-2322.	5.6	69
166	Medical, psychological and social correlates of work disability among men with Coronary artery disease. American Journal of Cardiology, 1986, 58, 911-915.	1.6	68
167	Expanding the Orbit of Primary Prevention — Moving beyond JUPITER. New England Journal of Medicine, 2008, 359, 2280-2282.	27.0	68
168	Chronic Kidney Disease and Risk for Presenting With Acute Myocardial Infarction Versus Stable Exertional Angina in Adults With Coronary Heart Disease. Journal of the American College of Cardiology, 2011, 58, 1600-1607.	2.8	66
169	Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 525-533.	2.2	66
170	Differential Dynamics of the Maternal Immune System in Healthy Pregnancy and Preeclampsia. Frontiers in Immunology, 2019, 10, 1305.	4.8	65
171	Physician practice in the management of congestive heart failure. Journal of the American College of Cardiology, 1986, 8, 966-970.	2.8	64
172	Adoption of thrombolytic therapy in the management of acute myocardial infarction. American Journal of Cardiology, 1988, 61, 510-514.	1.6	62
173	Insulin resistance independently predicts the progression of coronary artery calcification. American Heart Journal, 2009, 157, 939-945.	2.7	62
174	Validation of the Stanford Brief Activity Survey: Examining Psychological Factors and Physical Activity Levels in Older Adults. Journal of Physical Activity and Health, 2010, 7, 87-94.	2.0	62
175	Use of Medications for Secondary Prevention After Coronary Bypass Surgery Compared With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2013, 61, 295-301.	2.8	62
176	Comparative Effectiveness of Multivessel Coronary Bypass Surgery and Multivessel Percutaneous Coronary Intervention. Annals of Internal Medicine, 2013, 158, 727.	3.9	62
177	Association of Adverse Pregnancy Outcomes With Risk of Atherosclerotic Cardiovascular Disease in Postmenopausal Women. JAMA Cardiology, 2020, 5, 1390.	6.1	62
178	Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiology, 2019, 4, 128.	6.1	61
179	Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiological Genomics, 2007, 31, 402-409.	2.3	60
180	Persistent Racial Disparities in Survival After Heart Transplantation. Circulation, 2011, 123, 1642-1649.	1.6	60

#	Article	IF	CITATIONS
181	Economic Outcomes in the Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in Coronary Artery Disease Registry. Journal of the American College of Cardiology, 2014, 63, 1002-1008.	2.8	60
182	Differences in the Treatment of Myocardial Infarction Between the United States and Canada. Medical Care, 1995, 33, 598-610.	2.4	59
183	Cost-Effectiveness of Using High-Sensitivity C-Reactive Protein to Identify Intermediate- and Low-Cardiovascular-Risk Individuals for Statin Therapy. Circulation, 2010, 122, 1478-1487.	1.6	59
184	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of Cardiac Failure, 2016, 22, 659-669.	1.7	59
185	Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987. American Journal of Cardiology, 1988, 61, 515-518.	1.6	58
186	Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. American Heart Journal, 2007, 154, 1043-1051.	2.7	58
187	Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden. Journal of the American College of Cardiology, 2013, 61, 957-970.	2.8	58
188	Clinical judgement and therapeutic decision making. Journal of the American College of Cardiology, 1990, 15, 1-14.	2.8	57
189	The study of myocardial perfusion and coronary anatomy imaging roles in CAD (SPARC): design, rationale, and baseline patient characteristics of a prospective, multicenter observational registry comparing PET, SPECT, and CTA for resource utilization and clinical outcomes. Journal of Nuclear Cardiology. 2009. 16. 935-948.	2.1	56
190	Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. European Heart Journal, 2019, 40, 1963-1970.	2.2	56
191	Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. American Journal of Medicine, 2003, 115, 382-389.	1.5	55
192	Quality of life and time trade-off utility measures in patients with coronary artery disease. American Heart Journal, 2003, 145, 36-41.	2.7	55
193	Impact of the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act on Abdominal Ultrasonography Use Among Medicare Beneficiaries. Archives of Internal Medicine, 2012, 172, 1456.	3.8	55
194	Rethinking sensitivity and specificity. American Journal of Cardiology, 1987, 59, 1195-1198.	1.6	54
195	Functional capacity after cardiac surgery in elderly patients. Journal of the American College of Cardiology, 1994, 24, 104-108.	2.8	54
196	Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Human Genetics, 2008, 123, 399-408.	3.8	54
197	Incidental Pulmonary Nodules on Cardiac Computed Tomography: Prognosis and Use. American Journal of Medicine, 2008, 121, 989-996.	1.5	54
198	SYNTAX Score and Long-TermÂOutcomes. Journal of the American College of Cardiology, 2017, 69, 395-403.	2.8	54

#	Article	IF	CITATIONS
199	Type A behavior and survival: A follow-up study of 1,467 patients with coronary artery disease. American Journal of Cardiology, 1989, 64, 427-432.	1.6	53
200	Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial. Circulation, 2000, 102, 1375-1381.	1.6	53
201	Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial. Annals of Internal Medicine, 2014, 160, 594.	3.9	53
202	Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. American Heart Journal, 1999, 138, 376-383.	2.7	52
203	Incidental Findings on Cardiac Multidetector Row Computed Tomography Among Healthy Older Adults <subtitle>Prevalence and Clinical Correlates</subtitle> . Archives of Internal Medicine, 2008, 168, 756.	3.8	51
204	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. Catheterization and Cardiovascular Interventions, 2010, 76, E1-42.	1.7	51
205	Cost-Effectiveness of RevascularizationÂStrategies. Journal of the American College of Cardiology, 2015, 65, 1-11.	2.8	50
206	Early diagnosis of acute coronary syndrome. European Heart Journal, 2017, 38, 3049-3055.	2.2	50
207	Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among medicare beneficiaries. American Journal of Medicine, 2002, 112, 519-527.	1.5	49
208	Transcatheter Aortic Valve Replacement in Nonsurgical Candidates With Severe, Symptomatic Aortic Stenosis. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 419-428.	2.2	48
209	Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part II. Circulation, 2002, 106, 626-630.	1.6	47
210	The effect of obesity on quality of life in patients with diabetes and coronary artery disease. American Heart Journal, 2010, 159, 292-300.	2.7	47
211	Length of hospital stay after acute myocardial infarction in the Myocardial Infarction Triage and Intervention (MITI) Project registry. Journal of the American College of Cardiology, 1996, 28, 287-293.	2.8	45
212	Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. American Heart Journal, 2007, 154, 1052-1058.	2.7	45
213	Economic Outcomes of Treatment Strategies for Type 2 Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Circulation, 2009, 120, 2550-2558.	1.6	45
214	Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?. European Heart Journal, 2020, 41, 1346-1353.	2.2	45
215	The high cost of implantable defibrillators. European Heart Journal, 2007, 28, 388-391.	2.2	44
216	A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis, 2008, 198, 136-144.	0.8	44

#	Article	IF	CITATIONS
217	2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, e127-e145.	0.8	44
218	The Effect of Age on Outcomes of Coronary Artery Bypass Surgery Compared With Balloon Angioplasty or Bare-Metal Stent Implantation Among Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 2012, 60, 2150-2157.	2.8	44
219	Cost analysis of non-invasive fractional flow reserve derived from coronary computed tomographic angiography in Japan. Cardiovascular Intervention and Therapeutics, 2015, 30, 38-44.	2.3	44
220	Age-Specific Performance of the Revised Cardiac Risk Index for Predicting Cardiovascular Risk in Elective Noncardiac Surgery. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 103-108.	2.2	44
221	Syncope and Motor Vehicle Crash Risk. JAMA Internal Medicine, 2016, 176, 503.	5.1	44
222	Evaluation of Chest Pain in the Emergency Department. New England Journal of Medicine, 1997, 337, 1687-1689.	27.0	43
223	Use and accuracy of state death certificates for classification of sudden cardiac deaths in high-risk populations. American Heart Journal, 1997, 134, 1129-1132.	2.7	43
224	Feasibility and cost-saving potential of outpatient cardiac catheterization. Journal of the American College of Cardiology, 1990, 15, 378-384.	2.8	42
225	Cost-effectiveness as an outcome in randomized clinical trials. Clinical Trials, 2006, 3, 543-551.	1.6	42
226	Distribution of Asymmetric Dimethylarginine among 980 Healthy, Older Adults of Different Ethnicities. Clinical Chemistry, 2010, 56, 111-120.	3.2	42
227	Health Status After Treatment for Coronary Artery Disease and Type 2 Diabetes Mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Circulation, 2010, 122, 1690-1699.	1.6	42
228	Patient Preferences and Clinical Guidelines. JAMA - Journal of the American Medical Association, 1995, 273, 1219.	7.4	41
229	Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e879-e886.	1.6	41
230	The Incidence of Unrecognized Myocardial Infarction in Women with Coronary Heart Disease. Annals of Internal Medicine, 2001, 134, 1043.	3.9	39
231	Evidence-Based Use of Cardiac Procedures and Devices. New England Journal of Medicine, 2004, 350, 2126-2128.	27.0	39
232	Duke Activity Status Index for Cardiovascular Diseases: Validation of the Portuguese Translation. Arquivos Brasileiros De Cardiologia, 2014, 102, 383-90.	0.8	39
233	Cost-Effectiveness of a Conservative, Ischemia-Guided Management Strategy After Non–Q-Wave Myocardial Infarction. Circulation, 2002, 105, 680-684.	1.6	38
234	Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: A qualitative and quantitative angiographic study. American Journal of Cardiology, 1989, 63, 423-428.	1.6	37

#	Article	IF	CITATIONS
235	Physical and sexual function in women with chronic kidney disease. American Journal of Kidney Diseases, 2004, 43, 868-876.	1.9	37
236	Plasma Leptin Levels and Coronary Artery Calcification in Older Adults. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 729-732.	3.6	37
237	Acute Kidney Injury After CABG Versus PCI. Journal of the American College of Cardiology, 2014, 64, 985-994.	2.8	37
238	β-Blocker–Associated Risks in Patients With Uncomplicated Hypertension Undergoing Noncardiac Surgery. JAMA Internal Medicine, 2015, 175, 1923.	5.1	37
239	Natural history of patients with single-vessel disease suitable for percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 1983, 52, 225-229.	1.6	36
240	Susceptibility Loci for Clinical Coronary Artery Disease and Subclinical Coronary Atherosclerosis Throughout the Life-Course. Circulation: Cardiovascular Genetics, 2015, 8, 803-811.	5.1	36
241	Angina and associated healthcare costs following percutaneous coronary intervention: A realâ€world analysis from a multiâ€payer database. Catheterization and Cardiovascular Interventions, 2016, 88, 1017-1024.	1.7	36
242	Employment after Coronary Angioplasty or Coronary Bypass Surgery in Patients Employed at the Time of Revascularization. Annals of Internal Medicine, 1998, 129, 543.	3.9	35
243	Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease. American Heart Journal, 2002, 144, 390-396.	2.7	34
244	Lean body mass and risk of incident atrial fibrillation in post-menopausal women. European Heart Journal, 2016, 37, 1606-1613.	2.2	34
245	Innovation in Heart Failure Treatment. JACC: Heart Failure, 2018, 6, 401-409.	4.1	34
246	Evidence-Based Medicine And Policy: The Case Of The Implantable Cardioverter Defibrillator. Health Affairs, 2005, 24, 42-51.	5.2	33
247	The Effect of Age on Clinical Outcomes and Health Status. Journal of the American College of Cardiology, 2011, 58, 810-819.	2.8	33
248	Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease. Circulation, 2012, 126, S145-50.	1.6	33
249	Adoption and Effectiveness of Internal Mammary Artery Grafting in Coronary Artery Bypass Surgery Among Medicare Beneficiaries. Journal of the American College of Cardiology, 2014, 63, 33-39.	2.8	33
250	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e23-e106.	0.8	33
251	Comparative effectiveness of coronary artery bypass grafting and percutaneous coronary intervention for multivessel coronary disease in a community-based population with chronic kidney disease. American Heart Journal, 2013, 165, 800-808.e2.	2.7	32
252	Randomized comparison of the cost and effectiveness of iopamidol and diatrizoate as contrast agents for cardiac angiography. Journal of the American College of Cardiology, 1990, 16, 871-877.	2.8	31

#	Article	IF	CITATIONS
253	The associations of leptin, adiponectin and resistin with incident atrial fibrillation in women. Heart, 2016, 102, 1354-1362.	2.9	31
254	Racial and ethnic differences in atrial fibrillation risk factors and predictors in women: Findings from the Women's Health Initiative. American Heart Journal, 2016, 176, 70-77.	2.7	31
255	Clinical Utility of the Stanford Brief Activity Survey in Men and Women With Early-Onset Coronary Artery Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2007, 27, 227-232.	2.1	30
256	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Clinical Investigation, 2011, 41, 1010-1035.	3.4	30
257	Compelling Evidence for Coronary-Bypass Surgery in Patients with Diabetes. New England Journal of Medicine, 2012, 367, 2437-2438.	27.0	30
258	Recent Innovations, Modifications,ÂandÂEvolution of ACC/AHA Clinical Practice Guidelines: An Update for OurÂConstituencies. Journal of the American College of Cardiology, 2019, 73, 1990-1998.	2.8	30
259	Using databases to evaluate therapy. Statistics in Medicine, 1991, 10, 647-652.	1.6	29
260	Failure to replicate an association of SNPs in the oxidized LDL receptor gene (OLR1) with CAD. BMC Medical Genetics, 2008, 9, 23.	2.1	29
261	Ankle brachial index screening in asymptomatic older adults. American Heart Journal, 2011, 161, 979-985.	2.7	29
262	Late diagnosis of abdominal aortic aneurysms substantiates underutilization of abdominal aortic aneurysm screening for Medicare beneficiaries. Journal of Vascular Surgery, 2013, 57, 1519-1523.e1.	1.1	29
263	Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. Journal of the American College of Cardiology, 2016, 67, 1459-1469.	2.8	29
264	Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. European Heart Journal, 2019, 40, 3782-3790.	2.2	29
265	Coronary Artery Bypass Grafting and Cognitive Function. Journal of Cardiopulmonary Rehabilitation and Prevention, 1990, 10, 180-189.	0.5	28
266	Cost-Effectiveness of Genetic Testing in Family Members of Patients With Long-QT Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 76-84.	2.2	28
267	Distributed Decision Support Using a Web-based Interface. Medical Decision Making, 1999, 19, 157-166.	2.4	27
268	Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. American Heart Journal, 2002, 144, 422-430.	2.7	27
269	Self-rated health among women with coronary disease: Depression is as important as recent cardiovascular events. American Heart Journal, 2006, 152, 921.e1-921.e7.	2.7	27
270	The Dilemma of Incidental Findings on Cardiac Computed Tomography. Journal of the American College of Cardiology, 2009, 54, 1542-1543.	2.8	27

#	Article	IF	CITATIONS
271	Comparative Effectiveness of Clopidogrel in Medically Managed Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 2249-2257.	2.8	27
272	Cardiovascular Screening of Athletes. Clinical Journal of Sport Medicine, 2004, 14, 127-133.	1.8	26
273	Hypoglycemia and Elevated Troponin in Patients With Diabetes and CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2018, 72, 1778-1786.	2.8	26
274	Better functional status in American than Canadian patients with heart disease: An effect of medical care?. Journal of the American College of Cardiology, 1995, 26, 1115-1120.	2.8	25
275	Design and Baseline Characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) Trial fn1fn1This study was supported by the Department of Veterans Affairs Cooperative Studies Program, Palo Alto, California and Washington, D.C. and by a grant from Hoechst Marion Roussel, Inc., Kansas City, Missouri Journal of the American College of Cardiology, 1998, 31,	2.8	25
276	912-920. Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease. PPAR Research, 2009, 2009, 1-11.	2.4	25
277	Gaps in preoperative surveillance and rupture of abdominal aortic aneurysms among Medicare beneficiaries. Journal of Vascular Surgery, 2014, 59, 583-588.	1.1	25
278	Race and Ethnicity, Obesity, Metabolic Health, and Risk of Cardiovascular Disease in Postmenopausal Women. Journal of the American Heart Association, 2015, 4, .	3.7	25
279	Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia. American Journal of Cardiology, 1999, 84, 471-473.	1.6	23
280	Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. Annals of Internal Medicine, 2015, 163, 417-426.	3.9	23
281	Contemporary Burden and Correlates of Symptomatic Paroxysmal Supraventricular Tachycardia. Journal of the American Heart Association, 2018, 7, .	3.7	23
282	Unmet need for hypercholesterolemia care in 35 low- and middle-income countries: A cross-sectional study of nationally representative surveys. PLoS Medicine, 2021, 18, e1003841.	8.4	23
283	Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. American Journal of Cardiology, 1998, 82, 683-685.	1.6	22
284	Life after a ventricular arrhythmia. American Heart Journal, 2002, 144, 404-412.	2.7	22
285	Evaluation of Medicare claims data to ascertain peripheral vascular events in the Women's Health Initiative. Journal of Vascular Surgery, 2014, 60, 98-105.	1.1	22
286	Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ, The, 2015, 351, h5096.	6.0	22
287	High-sensitivity cardiac troponin I and incident coronary heart disease among asymptomatic older adults. Heart, 2016, 102, 1177-1182.	2.9	22
288	Administration of thrombolytic therapy in the community hospital: Established principles and unresolved issues. Journal of the American College of Cardiology, 1988, 12, A32-A43.	2.8	21

#	Article	IF	CITATIONS
289	Cost-effectiveness of the implantable cardioverter defibrillator?. Lancet, The, 2001, 357, 1817-1818.	13.7	21
290	Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995. American Heart Journal, 2002, 144, 397-403.	2.7	21
291	Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?. American Heart Journal, 2007, 154, 1059-1064.	2.7	21
292	Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 309-316.	2.2	21
293	Beta-blocker subtype and risks of perioperative adverse events following non-cardiac surgery: a nationwide cohort study. European Heart Journal, 2017, 38, 2421-2428.	2.2	21
294	Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006058.	2.2	21
295	Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 603-610.	2.2	20
296	Adverse Pregnancy Outcomes and Incident Heart Failure in the Women's Health Initiative. JAMA Network Open, 2021, 4, e2138071.	5.9	20
297	Right coronary wall cmr in the older asymptomatic advance cohort: positive remodeling and associations with type 2 diabetes and coronary calcium. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 75.	3.3	19
298	On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. European Journal of Cardio-thoracic Surgery, 2016, 49, 406-416.	1.4	19
299	Diagnostic Test Use in Different Practice Settings. Archives of Internal Medicine, 1983, 143, 1886.	3.8	18
300	Clinical correlates and prognostic significance of type A behavior and silent myocardial ischemia on the treadmill. American Journal of Cardiology, 1989, 64, 1280-1283.	1.6	18
301	Quality of life after coronary revascularization in the United States and Canada. American Journal of Cardiology, 2000, 85, 548-553.	1.6	18
302	Ethnic Differences in Coronary Artery Calcium in a Healthy Cohort Aged 60 to 69 Years. American Journal of Cardiology, 2007, 100, 981-985.	1.6	18
303	Physical Activity in Older Subjects Is Associated With Increased Coronary Vasodilation. JACC: Cardiovascular Imaging, 2011, 4, 622-629.	5.3	18
304	Women in Cardiology. Journal of the American College of Cardiology, 2016, 67, 542-544.	2.8	18
305	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	17
306	Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study. Lancet Regional Health - Europe, The, 2022, 14, 100308.	5.6	17

#	Article	IF	CITATIONS
307	Rheumatoid arthritis and coronary arteritis. American Journal of Cardiology, 1986, 57, 689-690.	1.6	16
308	Analysis of costs associated with CABG and PTCA. Annals of Thoracic Surgery, 1996, 61, s30-s32.	1.3	16
309	Management of ventricular arrhythmias in diverse populations in California. American Heart Journal, 2002, 144, 431-439.	2.7	16
310	The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 829-835.	0.8	16
311	Does Practice Variation Matter?. Journal of the American College of Cardiology, 2013, 62, 447-448.	2.8	16
312	Socioeconomic position and one-year mortality risk among patients with heart failure: A nationwide register-based cohort study. European Journal of Preventive Cardiology, 2020, 27, 79-88.	1.8	16
313	Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995. American Heart Journal, 2002, 144, 397-403.	2.7	16
314	Underuse of Evidence-Based Therapies. Circulation, 2004, 110, 644-645.	1.6	15
315	Adaptação cultural e avaliação da reprodutibilidade do Duke Activity Status Index para pacientes com DPOC no Brasil. Jornal Brasileiro De Pneumologia, 2012, 38, 684-691.	0.7	15
316	Effectiveness and Safety of Spironolactone for Systolic Heart Failure. American Journal of Cardiology, 2013, 112, 1427-1432.	1.6	15
317	Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts study. American Heart Journal, 2015, 170, 438-446.e44.	2.7	15
318	Women's Health Initiative Strong and Healthy Pragmatic Physical Activity Intervention Trial for Cardiovascular Disease Prevention: Design and Baseline Characteristics. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 725-734.	3.6	15
319	Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995. American Heart Journal, 2002, 144, 413-421.	2.7	15
320	Myocardial ischemia in constrictive pericarditis. American Heart Journal, 1988, 116, 1107-1111.	2.7	14
321	Patient preferences in coronary revascularization. American Heart Journal, 1999, 137, 1153-1162.	2.7	14
322	Role of economic models in randomized clinical trials. American Heart Journal, 1999, 137, S41-S46.	2.7	14
323	Projected long-term costs of coronary stenting in multivessel coronary disease based on the experience of the Bypass Angioplasty Revascularization Investigation (BARI). American Heart Journal, 2000, 140, 556-564.	2.7	14
324	Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995. American Heart Journal, 2002, 144, 413-421.	2.7	14

#	Article	IF	CITATIONS
325	Stents or Surgery?. Circulation, 2008, 118, 325-327.	1.6	14
326	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Epidemiology, 2011, 26, 313-337.	5.7	14
327	Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: A cohort study. BMC Nephrology, 2011, 12, 44.	1.8	14
328	Syncope and Its Impact on Occupational Accidents and Employment. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	14
329	Cost-Effectiveness of the Implantable Cardioverter Defibrillator. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 479-482.	1.0	13
330	Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 23, 2948-2956.	0.7	13
331	Repeat Revascularization Is a Faulty End Point for Clinical Trials. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 249-250.	2.2	13
332	Cost-Effectiveness of Transcatheter Aortic Valve Replacement. Circulation, 2012, 125, 1076-1077.	1.6	13
333	Outcomes After Coronary Artery Calcium and Other Cardiovascular Biomarker Testing Among Asymptomatic Medicare Beneficiaries. Circulation: Cardiovascular Imaging, 2014, 7, 655-662.	2.6	13
334	Fractional Flow Reserve Derived from Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain: Rationale and Design of the FORECAST Trial. Cardiovascular Revascularization Medicine, 2020, 21, 890-896.	0.8	13
335	Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. American Journal of Cardiology, 2020, 133, 116-125.	1.6	13
336	Quality of Life in Patients With Supraventricular Arrhythmia. Circulation, 1996, 94, 1491-1493.	1.6	13
337	Economic evaluation in long-term clinical trials. Statistics in Medicine, 2002, 21, 2879-2888.	1.6	12
338	The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction. American Heart Journal, 2011, 162, 494-500.e2.	2.7	12
339	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Human Genetics, 2011, 19, 615-615.	2.8	12
340	Framework for Evaluating Novel Risk Markers. Annals of Internal Medicine, 2012, 156, 468.	3.9	12
341	Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease. American Journal of Medicine, 2018, 131, 805-812.	1.5	12
342	Plasma Cholesterol. Archives of Internal Medicine, 1981, 141, 1132.	3.8	11

#	Article	IF	CITATIONS
343	Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrology Dialysis Transplantation, 2009, 24, 1956-1962.	0.7	11
344	Effectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease. Journal of Cardiac Failure, 2013, 19, 176-182.	1.7	11
345	An FFR _{CT} diagnostic strategy versus usual care in patients with suspected coronary artery disease planned for invasive coronary angiography at German sites: one-year results of a subgroup analysis of the PLATFORM (Prospective Longitudinal Trial of FFR _{CT} : Outcome) Tj ETQq1	1 0.7 8431	L4 <mark>11</mark> BT /Ove
346	Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias. Journal of Clinical Epidemiology, 1997, 50, 185-193.	5.0	10
347	Racial variation in lipoprotein-associated phospholipase A2in older adults. BMC Cardiovascular Disorders, 2011, 11, 38.	1.7	10
348	Impact of drug-eluting stents on the comparative effectiveness of coronary artery bypass surgery and percutaneous coronary intervention. American Heart Journal, 2015, 169, 149-154.	2.7	10
349	Considering Cost-Effectiveness in Cardiology Clinical Guidelines: Progress and Prospects. Value in Health, 2016, 19, 516-519.	0.3	10
350	ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients withÂstable ischemic heartÂdisease. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, e131-e161.	0.8	10
351	Socioeconomic position and first-time major cardiovascular event in patients with type 2 diabetes: a Danish nationwide cohort study. European Journal of Preventive Cardiology, 2022, 28, 1819-1828.	1.8	10
352	Task force 5: Profile of the cardiovascular specialist: Trends in needs and supply and implication for the American College of Cardiology, 1994, 24, 313-321.	2.8	9
353	Economic Endpoints in Clinical Trials. Epidemiologic Reviews, 2002, 24, 80-84.	3.5	9
354	Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. Journal of Clinical Epidemiology, 2011, 64, e1-e22.	5.0	9
355	Epidemiologic and Statistical Methods for Comparative Effectiveness Research. Heart Failure Clinics, 2013, 9, 29-36.	2.1	9
356	Cost of Initial Therapy in the Electrophysiological Study Versus ECG Monitoring Trial (ESVEM). Circulation, 1995, 91, 1070-1076.	1.6	9
357	Association of Premature Menopause With Risk of Abdominal Aortic Aneurysm in the Women's Health Initiative. Annals of Surgery, 2022, 276, e1008-e1016.	4.2	9
358	Angina, myocardial ischemia and coronary disease: Gold standards, operational definitions and correlations. Journal of Clinical Epidemiology, 1989, 42, 381-384.	5.0	8
359	Comparison of cardiovascular and renal toxicity after cardiac catheterization using a nonionic versus ionic radiographic contrast agent. American Journal of Cardiology, 1991, 68, 1117-1119.	1.6	8
360	Should we measure health-related quality of life?. American Heart Journal, 2000, 140, 359-360.	2.7	8

#	Article	IF	CITATIONS
361	Cardiac Resynchronization for Heart Failure. Annals of Internal Medicine, 2004, 141, 399.	3.9	8
362	A Pound of Prevention? Assessing the Value of New Cholesterol-Lowering Drugs. Annals of Internal Medicine, 2019, 170, 264.	3.9	8
363	Exercise testing to predict outcome in patients with angina. Journal of General Internal Medicine, 1999, 14, 63-65.	2.6	7
364	Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 2003, 91, 989-991.	1.6	7
365	Health-related Quality of Life Following Coronary Artery Bypass Graft Surgery in Post-menopausal Women. Journal of General Internal Medicine, 2008, 23, 1429-1434.	2.6	7
366	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy—Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. JAMA Cardiology, 2017, 2, 1066.	6.1	7
367	Temporal Trends in Mortality after Coronary Artery Revascularization in Patients with End-Stage Renal Disease. , 2014, 18, 11-16.		7
368	The importance of models in the assessment of synergy. Journal of Clinical Epidemiology, 1991, 44, 1287-1288.	5.0	6
369	Do Patients Prefer Physiologic Pacing?. New England Journal of Medicine, 1998, 338, 1147-1148.	27.0	6
370	Improvement in Quality of Life after Radiofrequency Ablation. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 341-342.	1.2	6
371	Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D). American Heart Journal, 2011, 162, 184-192.e3.	2.7	6
372	A risk score for predicting 30â€day mortality inÂheart failure patients undergoing non ardiac surgery. European Journal of Heart Failure, 2014, 16, 1310-1316.	7.1	6
373	Warfarin, Genes, and the (Health Care) Environment. JAMA Internal Medicine, 2014, 174, 1338.	5.1	6
374	Reply. Journal of the American College of Cardiology, 2014, 64, 741.	2.8	6
375	Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative. Journal of Vascular Surgery, 2021, 73, 1245-1252.e3.	1.1	6
376	Quality of Life After Fractional Flow Reserve–Guided PCI Compared With Coronary Bypass Surgery. Circulation, 2022, 145, 1655-1662.	1.6	6
377	Economic Evaluation of Alternative Strategies to Treat Patients with Diabetes Mellitus and Coronary Artery Disease. American Journal of Cardiology, 2006, 97, 59-65.	1.6	5
378	Incremental prognostic information from kidney function in patients with new onset coronary heart disease. American Heart Journal, 2014, 167, 86-92.	2.7	5

#	Article	IF	CITATIONS
379	Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. American Journal of Cardiology, 2020, 125, 553-561.	1.6	5
380	Willingness to Pay for High-Cost Medications. Circulation, 2020, 141, 1225-1226.	1.6	5
381	Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study. International Journal of Cardiology, 2020, 305, 120-126.	1.7	5
382	Driving following defibrillator implantation: a nationwide register-linked survey study. European Heart Journal, 2021, 42, 3529-3537.	2.2	5
383	The mediating role of effective treatments in the relationship between income level and survival in patients with heart failure: a sex- and cohabitation-stratified study. European Journal of Preventive Cardiology, 2021, 28, 78-86.	1.8	5
384	Effect of type A behavior on exercise test outcome in coronary artery disease. American Journal of Cardiology, 1990, 66, 179-182.	1.6	4
385	The Confirmatory Trial in Comparative-Effectiveness Research. New England Journal of Medicine, 2009, 361, 1498-1499.	27.0	4
386	Vascular Surgery Patients Prescribed Preoperative β-Blockers Experienced a Decrease in the Maximal Heart Rate Observed During Induction of General Anesthesia. Journal of Cardiothoracic and Vascular Anesthesia, 2012, 26, 414-419.	1.3	4
387	Volume, outcome, and policy. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 151-155.	1.3	4
388	Manuscripts Based on Datasets Shared by Clinical Research Studies. Journal of the American College of Cardiology, 2017, 69, 1983-1985.	2.8	4
389	New Method for Assessing the Effect of Driving Distance to Hospital Care. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	4
390	RESPONSE: A Mentor's Perspective on Using Shared Research Data. Journal of the American College of Cardiology, 2018, 71, 2077-2078.	2.8	4
391	Evaluation of diagnostic tests. Journal of Chronic Diseases, 1986, 39, 357-358.	1.2	3
392	The Value of BNP Testing. Archives of Internal Medicine, 2006, 166, 1063.	3.8	3
393	Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes. Evidence-Based Medicine, 2007, 12, 169-170.	0.6	3
394	Vision and Creation of the American Heart Association Pharmaceutical Roundtable Outcomes Research Centers. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 663-670.	2.2	3
395	Effect of Race on the Clinical Outcomes in the Bypass Angioplasty Revascularization Investigation Trial. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 186-190.	2.2	3
396	What We Can Learn From a Decision Model. Archives of Internal Medicine, 2011, 171, 667-8.	3.8	3

#	Article	IF	CITATIONS
397	Effectiveness Is the Key to Cost-Effectiveness. Circulation, 2013, 127, 764-765.	1.6	3
398	To Test or Not to Test, That Is the Question. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 207-208.	2.2	3
399	A Long-Term Perspective on Short-Term Outcomesâ^—. Journal of the American College of Cardiology, 2014, 64, 2109-2110.	2.8	3
400	A Delicate Balance. Journal of the American College of Cardiology, 2015, 65, 477-479.	2.8	3
401	Fiscal Fitness?. Journal of the American College of Cardiology, 2015, 66, 1886-1887.	2.8	3
402	Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials. American Heart Journal, 2018, 198, 108-114.	2.7	3
403	Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions — proceedings from the CEC Summit 2018. American Heart Journal, 2022, 246, 93-104.	2.7	3
404	Economic evaluation of low osmolality contrast media. Journal of the American College of Cardiology, 1993, 21, 1710-1711.	2.8	2
405	Cost Reduction and Implantable Cardioverter Defibrillator Implantation. Journal of Cardiovascular Electrophysiology, 2001, 12, 167-168.	1.7	2
406	Economic implications of transesophageal echocardiography-guided cardioversion of atrial fibrillation**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. Journal of the American College of Cardiology, 2004, 43, 1225-1227.	2.8	2
407	Comparative Effectiveness of Multivessel Coronary Artery Bypass Graft Surgery and Multivessel Percutaneous Coronary Intervention. Annals of Internal Medicine, 2013, 159, 435.	3.9	2
408	Highlights of the Year in JACC 2013. Journal of the American College of Cardiology, 2014, 63, 570-602.	2.8	2
409	Trial to Assess Chelation Therapy (TACT) and equipoise: When evidence conflicts with beliefs. American Heart Journal, 2014, 168, 4-5.	2.7	2
410	Are Novel Anticoagulants Worth Their Cost?. JAMA Cardiology, 2017, 2, 534.	6.1	2
411	Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL). American Heart Journal, 2022, 252, 39-41.	2.7	2
412	Analysis of risk factors for sudden death after acute myocardial infarction. American Journal of Cardiology, 1985, 55, 621-622.	1.6	1
413	Economic and Ethical Considerations in Percutaneous Coronary Revascularization. Journal of Interventional Cardiology, 1996, 9, 469-473.	1.2	1
414	Cost-Effectiveness of the Implantable Cardioverter Defibrillator. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 104-106.	1.0	1

#	Article	IF	CITATIONS
415	Does enrollment in a randomized clinical trial lead to a higher cost of routine care?. American Heart Journal, 2002, 143, 140-144.	2.7	1
416	The Year in Epidemiology, Health Services Research, and Outcomes Research. Journal of the American College of Cardiology, 2009, 53, 1459-1466.	2.8	1
417	Highlights of the Year in JACC2009. Journal of the American College of Cardiology, 2010, 55, 380-407.	2.8	1
418	Highlights of the Year in JACC 2010. Journal of the American College of Cardiology, 2011, 57, 480-514.	2.8	1
419	The Year in Epidemiology, Health Services Research, and Outcomes Research. Journal of the American College of Cardiology, 2011, 57, 1859-1866.	2.8	1
420	Highlights of the Year in JACC 2011. Journal of the American College of Cardiology, 2012, 59, 503-537.	2.8	1
421	Foreword: health policy and cardiac electrophysiology. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 97-97.	1.3	1
422	Highlights of the Year in JACC 2012. Journal of the American College of Cardiology, 2013, 61, 357-385.	2.8	1
423	Atrial Fibrillation Ablation, Symptoms, and Stroke Risk. JAMA Internal Medicine, 2013, 173, 156.	5.1	1
424	Effectiveness of preoperative beta-blockade on intra-operative heart rate in vascular surgery cases conducted under regional or local anesthesia. SpringerPlus, 2014, 3, 227.	1.2	1
425	Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies. Annals of Internal Medicine, 2014, 161, 378.	3.9	1
426	Review: In diabetes with multivessel or left main CAD, PCI increases death/MI/stroke combo compared with CABG. Annals of Internal Medicine, 2015, 162, JC8.	3.9	1
427	Galectin-3 and incident heart failure among patients with pre-existing coronary artery disease: The ADVANCE study. Clinical Trials and Regulatory Science in Cardiology, 2015, 5, 1-7.	1.0	1
428	Disentangling the Effects of Socioeconomic Factors on Outcomes Among Patients With HeartÂFailure. JACC: Heart Failure, 2019, 7, 756-758.	4.1	1
429	Economic Comparisons of Coronary Angioplasty and Coronary Bypass Surgery. , 0, , 223-232.		1
430	Meta-analysis: Streptokinase reduces mortality in suspected myocardial infarction. ACP Journal Club, 1991, 114, 35.	0.1	1
431	Cardiac outcomes occurred more frequently with PCI than CABG or medical therapy in coronary artery disease. ACP Journal Club, 2004, 141, 57.	0.1	1
432	Projects and priorities in cardiovascular modeling. Journal of the American College of Cardiology, 1989, 14, A52-A56.	2.8	0

#	Article	IF	CITATIONS
433	Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints. Contemporary Clinical Trials, 1990, 11, 268.	1.9	0
434	Preoperative Cardiac Evaluation and Perioperative Monitoring for Noncardiac Vascular Surgery-Reply. JAMA - Journal of the American Medical Association, 1995, 274, 1672.	7.4	0
435	Cost and efficacy analysis in the ESVEM trial: Implications for diagnosis and therapy for ventricular tachyarrhythmias. Progress in Cardiovascular Diseases, 1996, 38, 371-376.	3.1	Ο
436	Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 319-321.	1.0	0
437	Multislice computed tomography detected coronary artery disease. Evidence-Based Medicine, 2006, 11, 24-24.	0.6	0
438	The Year in Epidemiology, Health Services Research, and Outcomes Research. Journal of the American College of Cardiology, 2009, 54, 2343-2351.	2.8	0
439	CABG versus PCI for multivessel coronary artery disease – Authors' reply. Lancet, The, 2009, 373, 2200.	13.7	0
440	Comparative Effectiveness Research in Heart Failure. Heart Failure Clinics, 2013, 9, ix.	2.1	0
441	Response to Letter Regarding Article, "Cost-Effectiveness of Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease and Abnormal Fractional Flow Reserve― Circulation, 2014, 129, e684.	1.6	0
442	Reply. Journal of the American College of Cardiology, 2014, 64, 2712.	2.8	0
443	The Value of Pharmacogenetic Testing—Reply. JAMA Internal Medicine, 2015, 175, 314.	5.1	0
444	Reply to Young et al. Clinical Infectious Diseases, 2015, 61, 1207-1208.	5.8	0
445	Association of β-Blocker Treatment With Adverse Outcomes in Hypertensive Patients Undergoing Noncardiac Surgery—Reply. JAMA Internal Medicine, 2016, 176, 563.	5.1	0
446	Syncope While Driving in Denmark—Reply. JAMA Internal Medicine, 2016, 176, 1230.	5.1	0
447	Replace or Repair?. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e005093.	2.2	0
448	Same-day discharge after elective percutaneous coronary intervention was noninferior for safety to staying overnight in hospital. ACP Journal Club, 2007, 147, 35.	0.1	0
449	Review: Rosiglitazone increases risk for MI but does not differ from other drugs for CV death in type 2 diabetes. ACP Journal Club, 2007, 147, 66.	0.1	0
450	Rosiglitazone increased heart failure but did not differ from metformin plus sulfonylurea for other CV outcomes at interim analysis. ACP Journal Club, 2007, 147, 67.	0.1	0

#	Article	IF	CITATIONS
451	Same-day discharge after elective percutaneous coronary intervention was noninferior for safety to staying overnight in hospital. ACP Journal Club, 2007, 147, 35.	0.1	0
452	Review: rosiglitazone increases risk for MI but does not differ from other drugs for CV death in type 2 diabetes. ACP Journal Club, 2007, 147, 66.	0.1	0
453	Rosiglitazone increased heart failure but did not differ from metformin plus sulfonylurea for other CV outcomes at interim analysis. ACP Journal Club, 2007, 147, 67.	0.1	0
454	Immediate angioplasty was better than streptokinase in acute MI. ACP Journal Club, 1994, 121, 42.	0.1	0
455	Review: Early coronary bypass graft surgery lowers mortality. ACP Journal Club, 1995, 122, 29.	0.1	0
456	Captopril but not mononitrate or intravenous magnesium reduced short-term mortality after suspected myocardial infarction. ACP Journal Club, 1995, 123, 44.	0.1	0
457	Hospitalization for more than 3 days after thrombolysis for uncomplicated myocardial infarction was not cost-effective. ACP Journal Club, 2000, 133, 120.	0.1	0
458	Clopidogrel reduced recurrent ischemic events in patients with previous cardiac surgery more than did aspirin. ACP Journal Club, 2001, 135, 5.	0.1	0
459	Early postinfarction angina with ST-T changes was associated with poorer clinical outcomes. ACP Journal Club, 1992, 116, 57.	0.1	0
460	Stents had similar clinical outcomes but more repeated revascularization than did bypass surgery in multivessel disease. ACP Journal Club, 2001, 135, 89.	0.1	0
461	Familial Resemblance in Lowâ€Density Lipoprotein Cholesterol Response to Statins in the Danish Population, Journal of the American Heart Association, 2022, 11	3.7	Ο